This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Institute of Nuclear Energy Research. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Innovations in Alzheimer's Treatment: The Contributions of Han-Hsiang Chu
Introduction: Han-Hsiang Chu is a notable inventor based in Taoyuan, Taiwan, recognized for his significant contribution to the field of Alzheimer’s research. With one patent to his name, his work focuses on developing innovative compounds aimed at improving clinical diagnostics for Alzheimer’s syndrome.
Latest Patents: Han-Hsiang Chu holds a patent titled *Compounds of Imaging Agent with HDAC Inhibitor for Treatment of Alzheimer Syndrome and Method of Synthesis Thereof*. This patent details a method of synthesizing an imaging agent combined with a histone deacetylase (HDAC) inhibitor. The method includes providing an HDAC inhibitor in conjunction with the compound that features HDAC inhibitor BNL-26 and its analogs, labeled with the radionuclide F-18. The result is a series of nuclear medicine tracers, including BNL-26-CHCH18F and various analogs, which can assist in binding to over-expressed HDAC and facilitate nuclear medicine imaging effects crucial for clinical diagnosis.
Career Highlights: Han-Hsiang Chu is a valuable asset to the Institute of Nuclear Energy Research, where he has honed his expertise and contributed to significant advancements in nuclear medicine. His innovative approach in synthesizing compounds has opened new avenues for Alzheimer's treatment and diagnosis, marking a pivotal moment in the intersection of nuclear medicine and neurodegenerative disease research.
Collaborations: Throughout his career, Han-Hsiang Chu has collaborated with esteemed colleagues, including Ming-Hsin Li and Chyng-Yann Shiue. These partnerships have fostered an environment of innovation and knowledge exchange, enhancing the impact of their collective research efforts.
Conclusion: Han-Hsiang Chu stands out as an influential inventor in the field of Alzheimer's treatment, with a unique patent that showcases his dedication to improving clinical diagnostics. His work at the Institute of Nuclear Energy Research, combined with fruitful collaborations, continues to pave the way for future innovations in medical research and patient care.